Medexus Pharmaceuticals Inc. MEDXF
OTC PK
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 29.10M | 28.59M | 24.65M | 25.32M | 24.74M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.10M | 28.59M | 24.65M | 25.32M | 24.74M |
| Cost of Revenue | 10.48M | 10.34M | 9.00M | 9.39M | 8.60M |
| Gross Profit | 18.62M | 18.25M | 15.65M | 15.93M | 16.14M |
| SG&A Expenses | 13.30M | 12.99M | 10.59M | 11.22M | 11.92M |
| Depreciation & Amortization | 2.42M | 2.41M | 2.46M | 2.42M | 2.43M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.66M | 26.47M | 23.00M | 23.65M | 23.09M |
| Operating Income | 2.44M | 2.11M | 1.66M | 1.68M | 1.65M |
| Income Before Tax | 1.22M | 501.00K | -3.01M | 446.00K | -327.00K |
| Income Tax Expenses | 410.00K | -43.00K | -333.00K | 366.00K | -12.00K |
| Earnings from Continuing Operations | 813.00K | 544.00K | -2.68M | 80.00K | -315.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 813.00K | 544.00K | -2.68M | 80.00K | -315.00K |
| EBIT | 2.44M | 2.11M | 1.66M | 1.68M | 1.65M |
| EBITDA | 4.86M | 4.53M | 3.94M | 4.10M | 4.08M |
| EPS Basic | 0.03 | 0.02 | -0.08 | 0.00 | -0.01 |
| Normalized Basic EPS | 0.02 | 0.01 | 0.00 | 0.01 | 0.00 |
| EPS Diluted | 0.03 | 0.02 | -0.08 | 0.00 | -0.01 |
| Normalized Diluted EPS | 0.02 | 0.01 | 0.00 | 0.01 | 0.00 |
| Average Basic Shares Outstanding | 31.43M | 31.83M | 32.29M | 32.43M | 32.29M |
| Average Diluted Shares Outstanding | 31.43M | 31.83M | 32.29M | 32.43M | 32.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |